JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Management of lower urinary tract symptoms in men with progressive neurological disease.

PURPOSE OF REVIEW: Progressive neurological disease can cause lower urinary tract symptoms similar to those seen in bladder outflow obstruction. Increasingly common with age, these two groups of conditions often coexist. The complex pathophysiology of men with this combination of problems is often poorly understood and suboptimally managed, mostly with long-term indwelling catheters. This review looks at recent diagnostic advances and emerging therapeutic alternatives.

RECENT FINDINGS: For various neurogenic bladder disorders, urodynamic studies may demonstrate typical constellations of abnormalities, but no pathognomonic features. Other modalities such as sphincter electromyography and central nervous system imaging have been proposed to aid diagnosis. Functional brain imaging has helped to understand the complex nature of bladder storage and micturition control. A new generation of bladder-selective antimuscarinics has graduated through phase-III randomized controlled trials and these are now available for routine use. These agents are as efficacious as oxybutynin but have better side-effect profiles. Modern minimally invasive techniques such as desensitizing bladder instillations or injections of botulinum toxin have safely been used and are achieving excellent results.

SUMMARY: Urodynamic studies are important and increasingly regarded as mandatory in all men considered for outflow surgery. Neurogenic bladder and sphincter dysfunction can be managed conservatively or with new minimally invasive techniques. Surgery should be reserved for severely symptomatic treatment failures. A working knowledge of common neurological disease associated with lower urinary tract dysfunction is important for urologists to diagnose these conditions or initiate an appropriate referral. This article gives an overview of recent work that has implications for the diagnosis and management of neurological disorders of micturition.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app